Drug Profile

4CB 1

Alternative Names: 4CB-1; Alpha 4CB-1.1; Anti-4CB1; α4CB-1.1

Latest Information Update: 27 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 4C Biomed
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; Tumour necrosis factor ligand superfamily member 14 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer

Most Recent Events

30 Apr 2024 4C Biomed plans a clinical trial for Cancer in third quarter of 2025
02 Apr 2024 Adverse events and pharmacodynamics data from a preclinical trial in Cancer released by 4C Biomed (4C Biomed pipeline, April 2024)
29 Sep 2021 Preclinical trials in Cancer in United Kingdom (Parenteral) (4C Biomed pipeline, September 2021)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com